Submitted:
13 February 2024
Posted:
13 February 2024
You are already at the latest version
Abstract
Keywords:
1. Introduction
2. Materials and Methods
STATISTIC ANALYSIS
3. Results
Sociodemographic and clinical characteristics of the population
Glycemic Control and Ankle Brachial Index
Relationship between glycemic control and peripheral arterial disease
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Zhang P, Lu J, Jing Y, Tang S, Zhu D, Bi Y. Global epidemiology of diabetic foot ulceration a systematic review and meta-analysis.Annals of Medicine. 2017;49(2):106-16. [CrossRef]
- Carro GV, Saurral R,Salvador F, Witman EL. Pie diabético en pacientes internados en hospitales de Latinoamérica. MEDICINA. 2018;78:243-51.PMID: 30125251. 3012.
- Ramos W, Lopez T, Revilla L, More L, Huamaní M, Pozo M. Resultados de la vigilancia epidemiológica de diabetes mellitus en hospitales notificantes del Perú. 2012. Rev. Perú. Med. Exp. Salud Pública. 2014;3:9-15. [CrossRef]
- Yovera M, Sáenz S, Quispe Y, Agüero R, Salcedo J, Sarria C, et al. Nationwide prevalence and clinical characteristics of in patient diabetic foot complications: A Peruvian multicenter study. Prim. Care Diab. 2021;1-8. [CrossRef]
- Tyagi V, Gupta A, Bansal N, Virmani SK. Prevalence of peripheral artery disease in diabetes mellitus: research article. Int J Res Med Sci. 2017;5(11): 4881-5. [CrossRef]
- Selvin E, Marinopoulos S, Berkenblit G, Rami T, Brancati FL, Powe NR et al. Meta-analysis: glycosylated hemoglobin and CVD disease in diabetes mellitus. Ann Intern Med. 2004;21:421-31. [CrossRef]
- UKPDS Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837-53. PMID: 9742976. [CrossRef]
- Lu Q, Wang J, Wei X, Wang G, Xu Y, Lu Z, et al. Costo of diabetic foot ulcer management in China. A 7- year single-center retrospective review. Diabetes, Metabolic Sindrome and Obesity: Targets and Therapy. 2020;13:4249-60. [CrossRef]
- American Diabetes Association. Standards of medical care in diabetes 2019. Diabetes Care. 2019;42 Suppl 1:S1-193. [CrossRef]
- International Diabetes Federation. IDF Clinical Practice Recommendations on the Diabetic Foot. 2017. [Internet] International Diabetes Federation. [cited 2022 Oct 15]. Available from: https://www.idf.org/e-library/guidelines/119-idf-clinical-practice-recommendations-on-diabetic-foot-2017.html.
- Martínez-De Jesús F, Ibrahim A, Rodriguez N, Zambrano E. The latin American Saint Elian wound score system (SEWSS) for the triage of the diabetic foot attack. Cir Cir.2021;89(5):679-85. [CrossRef]
- The International Working Group on the Diabetic Foot. The 2019 IWGDF Practical guidelines on the prevention and management of diabetic foot disease. [internet] International Working Group on the Diabetic Foot [cited 2020 May 10]. [CrossRef]
- Martínez-De Jesús F, Hernandez E, Rodriguez N, Cendejas R, Muñoa J, Carrera F, et al. Validation of the Ischaemia Severity Scale (ISS) based on non-invasive vascular assessments (SEWSS) for outcomes prediction in diabetic foot attack. J.Clin.Med.2021;10:1-11. [CrossRef]
- Kim SG, Hahm JR, Kim DK, Cho SR, Choi DS. Assessment of glycemic control in patients with type 2 diabetes mellitus treated with metformin-sulfonylurea combination: Results of a multicenter, cross-sectional, observational study in Korea. J Diabetes Invest. 2015;6:317-24. [CrossRef]
- Brož J, Žďárská DJ, Urbanová J, Brabec M, Doničová V, Štěpánová R, et al. Current Level of Glycemic Control and Clinical Inertia in Subjects Using Insulin for the Treatment of Type 1 and Type 2 Diabetes in the Czech Republic and the Slovak Republic: Results of a Multinational, Multicenter, Observational Survey (DIAINFORM). Diabetes Ther. 2018;9:1897–906. [CrossRef]
- Jasso LE, Villena A, Guevara X. Control metabólico en pacientes diabéticos ambulatorios de un hospital general. Rev Med Hered. 2015;26:167-72. [CrossRef]
- Charles M, Ejskjaer N, Witte DR, Borch-Johnsen K, Lauritzen T, Sandbaek A. Prevalence of neuropathy and peripheral arterial disease and the impact of treatment in people with screen-detected type 2 diabetes. Diabetes Care. 2011;34:2244-9. [CrossRef]
- Shukla V, Fatima J, Ali M, Grag A. A study of prevalence of peripheral arterial disease in type 2 diabetes mellitus patients in a teaching hospital. J Assoc Physicians India. 2018;66:57-60. PMID: 30477058.
- Ayala M, Garcia A. Association between peripheral arterial disease and diabetic foot ulcers in patients with diabetes mellitus type 2.Medicina Universitaria. 2017;19(76):123-6. [CrossRef]
- Potier L, Abi-Khalil C, Mohammedi K, Roussel R. Use and utility of ankle brachial index in patients with diabetes. Eur J Vasc Endovasc Surg. 2011; 41:110-6. [CrossRef]
- Kuo-Chin H, Ching-Chu C, Yi-Chang S, Jui-Shan L, Chwen-Tzuei C, Tzu-Yuan W, et al. The relationship between stasis-stagnation constitution and peripheral arterial disease in patients with type 2 diabetes. Evidence-Based Complementary and Alternative Medicine. 2014:1-6. [CrossRef]
- Zhang S, Yongcai Z, yan Z, Shaoqing L.Risk factors for peripheralarterial disease in elderly patients with type-2 diabetes mellitus:A clinical study. Pak J Med Sci.2020;36(6):1344-48. [CrossRef]
- Unkart J, Allison M, Parada H, Criqui M, Qi Q, Diaz K, et al.Sedentary time and peripheral artery disease: The Hispanic community health study/study of latinos.Am Heart J.2020;222:208-19. [CrossRef]
- Muntner P, Wildman R, Reynolds K, DeSalvo K, Chen J, Fonseca V.Relationship between HbA1c level and peripheral arterial disease. Diabetes Care 2005;28:1981-7. [CrossRef]
- Selvin E, Wattanakit K, Steffes M, Coresh J, Richey A.HbA1c and peripheral arterial disease in diabetes. Diabetes Care 2006;29:877-82. [CrossRef]
- Seong-Woo C, Min-Ho S, Woo-Jun Y, Hey-Yeon K, Young-Hoon L, Sun-Seog K, et al. Association between hemoglobin A1c,carotid atherosclerosis, arterial stiffness, and peripheral arterial disease in Korean type2 diabetic patients.Journal of Diabetes and Its complications 2011;25:7-13. [CrossRef]
- Ishii H, Kumada Y, Takahashi H, Toriyama T, Aoyama T, Tanaka M et al. Impact of diabetes and glycaemic control on peripheral artery disease in Japanese patients with end-stage renal disease: long-term follow-up study from the beginning of haemodialysis. Diabetologia. 2012;55:1304-09. [CrossRef]
- Solanki JD, Makwana AH, Mehta HB. Evaluating glycemic control and its correlation with peripheral artery disease in ambulatory type 2 diabetic patients of an urban area of Gujarat, India. Int J Clin Exp Physiol.2014;1:221-5. [CrossRef]
- Xiang J, Wang S, He Y, Lei X, Zhang S, Tang Z. Reasonable Glycemic Control Wound Help Wound Healing During the Treatment of Diabetic Foot Ulcers Diabetes Ther. 2019;10:95-105. [CrossRef]
- Thiruvoipati T, Kielhorn CE, Armstrong EJ. Peripheral artery disease in patients with diabetes: Epidemiology, mechanisms, and outcomes. World J Diabetes. 2015;6:961–9. [CrossRef]
| Sociodemographic characteristics | n=226 | % |
| Age | 67.4 SD&: 10.5 | |
| Gender | ||
| Male | 146 | 64.6 |
| Female | 80 | 35.4 |
| Current Job | ||
| Yes | 92 | 40.7 |
| No | 134 | 59.3 |
| Clinical characteristics | ||
| BMI* | 26.8 SD&: 4.1 | |
| Time with DM** | 20 IQR#: 13-25 | |
| Hypertension | ||
| Yes | 147 | 65 |
| No | 79 | 35 |
| Dyslipidemia | ||
| Yes | 169 | 74.8 |
| No | 57 | 25.2 |
| Obesity | ||
| Yes | 45 | 20 |
| No | 181 | 80 |
| Smoking | ||
| Yes | 33 | 14.6 |
| No | 193 | 85.4 |
| Sedentary Lifestyle | ||
| Yes | 87 | 38.5 |
| No | 139 | 61.5 |
| Saint Elián Score | 57 | 25.2 |
| Grade I | 13 | 23 |
| Grade II | 41 | 71.9 |
| Grade III | 3 | 5.2 |
| *BMI: body mass index, **Time DM: Time with diabetes mellitus type 2 | ||
|
&SD: Standard deviation, #IQR: Interquartile range | ||
| Ankle-Brachial Index (Yao) | |||||||||
| Total | PAD ( < 0.9 ) | Normal (0.91 - 1.3) | Calcified (> 1.3) | ||||||
| Glycemic Control | n (%) | n (%) | 95% CI | n (%) | 95% CI | n (%) | 95% CI | p-value* | |
| Yes (< 7%) | 52 (23.0) | 22 (21.8) | 14.7 - 31.1 | 21 (30.9) | 20.9 - 43.1 | 9 (15.8) | 8.3 - 28.1 | 0.126 | |
| No (≥ 7%) | 174 (77.0) | 79 (78.2) | 68.9 - 85.3 | 47 (69.1) | 56.9 - 79.1 | 48 (84.2) | 71.9 - 91.7 | ||
| Total | 226 (100.0) | 101 (44.7) | 38.3 - 51.3 | 68 (30.1) | 24.4 - 36.4 | 57 (25.2) | 20 - 31.3 | ||
| Unadjusted Model |
Adjusted Model * |
||||||
| PR (c) | 95% CI | p-value | PR (a) | 95% CI | p-value | ||
| Glycemic Control | |||||||
| Yes (<7%) | Ref | Ref | |||||
| No (>7%) | 1.23 | 0.89 - 1.69 | 0.217 | 1.34 | 1.01 - 1.79 | 0.045 | |
| Age | 1.02 | 1.01 - 1.04 | <0.001 | 1.02 | 1.01 - 1.03 | 0.005 | |
| Gender | |||||||
| Male | Ref | Ref | |||||
| Female | 1.03 | 0.80 - 1.33 | 0.807 | 1.07 | 0.83 - 1.37 | 0.573 | |
| Obesity | |||||||
| No | Ref | Ref | |||||
| Yes | 0.72 | 0.48 - 1.07 | 0.102 | 0.80 | 0.57 - 1.14 | 0.215 | |
| Hypertension | |||||||
| No | Ref | Ref | |||||
| Yes | 1.22 | 0.91 - 1.64 | 0.192 | 1.10 | 0.81 - 1.47 | 0.545 | |
| Dyslipidemia | |||||||
| No | Ref | Ref | |||||
| Yes | 0.79 | 0.62 - 1.01 | 0.065 | 0.94 | 0.07 - 1.21 | 0.622 | |
| Smoking | |||||||
| No | Ref | Ref | |||||
| Yes | 1.19 | 0.89 - 1.60 | 0.238 | 1.20 | 0.90 - 1.59 | 0.209 | |
| Sedentary lifestyle | |||||||
| No | Ref | Ref | |||||
| Yes | 1.51 | 1.18 - 1.93 | <0.001 | 1.40 | 1.10 - 1.78 | 0.007 | |
| * Adjusted for Age, Gender, Obesity, Hypertension, Dyslipidemia, Smoking, Sedentary lifestyle. | |||||||
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).